| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | 0.066 | 0.2 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.2 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.2 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.2 |
| mRNA | Epothilone B | GDSC1000 | pan-cancer | AAC | 0.044 | 0.2 |